Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
July 01 2014 - 8:30AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced it has independently confirmed MANF's activity in
mitigating tau hyperphosphorylation in pre-clinical models of
Alzheimer's disease. The studies commissioned by Amarantus
independently confirm data published in 2012 in the Chinese
Pharmacological Bulletin entitled "MANF Inhibits Tau
Hyperphosphorylation in Cultured Neuronal Cells" in which the
authors demonstrated that MANF had a pronounced effect in reducing
Tau hyperphosphorylation, reducing cell death, and improving
overall cellular health in in vitro models of Alzheimer's disease.
"There has been a high degree of concern of late that data
produced in China may not reproduce in Western labs," said Gerald
E. Commissiong, President & CEO of Amarantus. "We are extremely
pleased that the Company was able to reproduce these exciting
findings, especially in light of our growing interest in the Asian
market. What this tells us is that good science is currently being
conducted on MANF in China, and we believe we can leverage this to
the benefit of shareholders. China is continuing to emerge as a
powerhouse across all sectors, including biotechnology.
Establishing relationships in that part of the world early on will
be tremendously valuable as we seek to fully exploit our MANF
technology. Alzheimer's disease is a global problem that we believe
will require global solutions."
In in vitro models of Alzheimer's disease, MANF improved cell
viability and reduced tau hyperphosphorylation believed to be
directly associated with human Alzheimer's disease. The data
demonstrated a robust activity consistent with positive controls.
The Company will begin to map out a strategy to evaluate MANF
activity in animal models of Alzheimer's disease as part of its
broader MANF research program.
About Mesencephalic-Astrocyte-derived Neurotrophic
Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is
believed to have broad potential because it is a
naturally-occurring protein produced by the body for the purpose of
reducing and preventing apoptosis (cell death) in response to
injury or disease, via the unfolded protein response of the
endoplasmic reticulum. By manufacturing MANF and administering it
to the body, Amarantus is seeking to use a regenerative medicine
approach to assist the body with higher quantities of MANF when
needed. Amarantus is the front-runner and primary holder of
intellectual property (IP) around MANF, and is initially focusing
on the development of MANF-based protein therapeutics. MANF's
current lead indication is Retinitis Pigmentosa, and other
applications including Parkinson's disease, Alzheimer's disease and
Wolfram's Syndrome. Additional applications for MANF may include
Traumatic Brain Injury (TBI), myocardial infarction,
antibiotic-induced ototoxicity and certain other rare orphan
diseases currently under evaluation.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small
molecule indicated for Parkinson's Levodopa induced dyskinesia and
Adult ADHD. AMBS has an exclusive worldwide license to the
Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's
disease and owns the intellectual property rights to a therapeutic
protein known as Mesencephalic-Astrocyte-derived Neurotrophic
Factor ("MANF") and is developing MANF-based products as treatments
for brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024